



# **Metastatic Pancreatic Adenocarcinoma Research**

**Physician Screener**

**Version K – 7<sup>th</sup> July 2016 – Post pilots**

Prepared for Baxalta

## Screeener

To facilitate recruitment and fieldwork completion, we will allow recruiters to manually recruit doctors (over the phone or by email), before the survey is launched. A doctor who qualifies by means of manual recruitment will skip the online screener.

[SHOW ALL, 1<sup>st</sup> connection only]

Dear Doctor,

Thank you for your interest in our study (reference FG115M01) about the **treatment of metastatic pancreatic adenocarcinoma patients** conducted by Genactis and sponsored by a pharmaceutical company. The aim of this non-promotional market research is to understand physicians' usage of therapies for the treatment of metastatic pancreatic adenocarcinoma (and to understand their approach when treating different types of patients). The results will be published.

This study will be conducted over the internet from June 27<sup>th</sup> to end of November.

You will be asked to complete:

- A workload questionnaire (that should take approximately 10 min to complete)
- **[12 in EU5 and min 3-8 in Nordic (DK, NO, SE) and in NL]** retrospective anonymized patient records (PRs) of patients diagnosed with metastatic pancreatic adenocarcinoma who have received at least one line of therapy for metastatic disease. Each patient record collects data about the patient's disease characteristics and treatments. It should take approximately 25 minutes to complete each patient record.

**NUMBERING TO BE ALIGNED IN PROGRAMMING (APPLY TO SCREENER AND QUESTIONNAIRE)**

**Monitoring of cases will be done weekly. Quotas on second line (2L) will be added if needed (respondents forced to enter 2L cases)**

**Full honoraria will be given to participants entering 12 "2L patient cases". For 1L cases, honoraria will be reviewed.**

## Introduction and Screener

NOT TO BE PROGRAMMED- INSTRUCTIONS FOR RECRUITERS: Adverse Event (AE) reporting for nal-IRI will be if used in clinical trial or through EAP (if running), or international pharmacy (after US approval)  
[SHOW ALL, 1<sup>st</sup> connection only]

**We would like to reassure you that:**

- We will comply with all [Insert COUNTRY] laws protecting your personal data, the codes of [Insert relevant country specific MR and health care associations. e.g. UK: "MRS, BHBIA and ABPI Code of conduct"].

Your responses will be used by us and the sponsoring pharmaceutical company for market research purposes and may also be published by the sponsoring company (in an aggregated and anonymized form).

- Your responses will be collated with other respondents and presented to the sponsor in aggregated or anonymized form.
- We are now being asked to pass on to our client details of adverse events and product complaints that are mentioned during the course of market research. Although what you say will, of course, be treated in confidence, should you raise during the discussion/survey an adverse event in a specific patient, we will need to report this even if it has already been reported by you directly to the company or the regulatory authorities.
- In such a situation you will be asked whether or not you are willing to waive the confidentiality given to you under the Market Research Codes of Conduct specifically in relation to that adverse event. Everything else you say during the course of the interview/survey will continue to remain confidential, and you will still have the option to remain anonymous if you so wish.
- Your responses will be otherwise confidential and will not be used for any other purposes or disclosed to any third party without your approval.
- The results (in an aggregated and anonymized form) may also be used in publications by the sponsoring company.
- We remind you that you may at all times request a copy of your personal information, have it corrected and object to its processing by contacting Genactis.

You have the right to withdraw from the interview at any time.

Are you happy to participate with the survey on these bases?

## Introduction and Screener

**CONFIDENTIALITY AGREEMENT:** You acknowledge that in the course of this study, proprietary information regarding products and product development, and other trade secrets and know-how may be disclosed, and by participating in this study you agree to hold all such information confidential and to not disclose it to any third party or use it for any other purpose whatsoever. You also agree not to disclose any part of the following pages, which is proprietary material of Genactis and its client. You are required to accept the above confidentiality agreement in order to participate in this survey. Please indicate whether or not you accept:

1. Yes	<a href="#">[CONTINUE]</a>
2. No	<a href="#">[TERMINATE]</a>

Before we begin, however, we would like to ask you a few qualifying questions. This will take one minute.

## Screener

**SQ1. Country [PREFILLED].**

1. France
2. Germany
3. Italy
4. Spain
5. UK
6. Netherlands
7. Denmark
8. Norway
9. Sweden

**SQ1\_1. Please indicate your region**

Translators to note down the regions falling into each category		
e.g. Paris et Région Parisienne	Capital and its region	<b>1</b>
e.g. "Not applicable" can be an option for some regions countries	N	<b>2</b>
	NW	<b>3</b>
	NE	<b>4</b>
	Centre	<b>5</b>
	S	<b>6</b>
	SW	<b>7</b>
	SE	<b>8</b>

## Introduction and Screener

**SQ2.** What is your main specialty? (Tick only one)

<b>Medical oncology</b>	<b>1</b>	
<b>Haemato-oncology</b>	<b>2</b>	
<b>Internal medicine</b>	<b>3</b>	<b>[Germany Only]</b>
<b>Gastroenterology</b>	<b>4</b>	<b>[France and Germany Only]</b>
<b>Other</b>	<b>5</b>	<b>[TERMINATE]</b>

**[GERMANY ONLY, SHOW IF SQ2=3]**

**SQ2a.** What is your area of specialization? (Tick only one)

<b>Oncology</b>	<b>1</b>	
<b>Other</b>	<b>3</b>	<b>[TERMINATE]</b>

**[FRANCE AND GERMANY ONLY, SHOW IF SQ2=4]**

**SQ2b.** What is your area of specialization? (Tick only one)

<b>Oncology</b>	<b>1</b>	<b>40% maximum in DE 20% maximum in FR</b>
<b>Other</b>	<b>2</b>	<b>[TERMINATE]</b>

## Introduction and Screener

[\[SHOW ALL\]](#)SQ3. Where do you spend most of your practice time? (Tick only one)

<b>Academic / teaching / University hospital</b>	<b>1</b>	
<b>General hospital</b>	<b>2</b>	
<b>Private hospital / Clinic</b>	<b>3</b>	
<b>Specialized / Cancer Centre</b>	<b>4</b>	
<b>Office</b>	<b>5</b>	<b>[GERMANY ONLY]</b> <b>20% maximum</b>
<b>Other</b>	<b>6</b>	<b>[TERMINATE]</b>

[\[SHOW IF SQ3=1, 2, OR 3\]](#)

SQ3\_1. Please indicate if you work in a specialized centre or Reference centre (Tick only one)

<b><u>Independent</u> Specialised Cancer Centre / Reference Centre (not belonging to a hospital)</b>	<b>1</b>
<b>Specialized Cancer Centre / Reference Centre <u>belonging</u> to a hospital</b>	<b>2</b>
<b>My hospital / clinic is not specialized Cancer Centre / Reference Centre</b>	<b>3</b>

[\[SHOW ALL\]](#)

SQ3\_2. Please indicate your role in the hospital / in your practice

<b>Staff / specialist</b>	<b>1</b>	
<b>Professor</b>	<b>2</b>	
<b>Resident / in training / in specialisation</b>	<b>3</b>	
<b>Other</b>	<b>4</b>	

[\[SHOW ALL\]](#)

SQ4. Please indicate the year you qualified as a specialist

Year of specialisation:    [\[TERMINATE IF 1976 > y > 2012\]](#)[\[IF <1960 THEN INSERT MESSAGE: PLEASE](#)[CHECK YOUR ANSWER\]](#)

## Introduction and Screener

**[SHOW ALL]**

**SQ5.** Over the last twenty-four months, in total, how many patients with a diagnosis of **metastatic pancreatic adenocarcinoma** did you see/consult on /treat directly? To clarify, these were patients for whom you were personally involved in making treatment decisions. (Please count each **patient** once and not the number of visits).

# of patients for whom you were personally involved in making treatment decisions in the last 24 months : _____
---

FR, GER, IT, SP, UK	NL, DK, NO, SE
TERMINATE IF SQ5<15	TERMINATE IF SQ5<8

**SQ6.** Over the last twenty-four months, how many **metastatic pancreatic adenocarcinoma** patients in total did you see that received **first line treatment for metastatic disease**? (Please count each patient once and not the number of visits).

# of patients seen who received FIRST line in the last 24 months : _____
--

**[SQ6 MUST <=SQ5]**

FR, GER, IT, SP, UK	NL, DK, NO, SE
TERMINATE IF SQ6<10	TERMINATE IF SQ6<4

**SQ7.** Over the last twenty-four months, how many **metastatic pancreatic adenocarcinoma** patients in total did you see that received **a second line treatment for metastatic disease**? (Please count each patient once and not the number of visits).

# of patients seen who received SECOND line in the last 24 months : _____
---

FR, GER, IT, SP, UK	NL, DK, NO, SE
TERMINATE IF SQ7<3	TERMINATE IF SQ7<1



## Introduction and Screener

**[Screen out message]**

Thank you for answering our screening questions. Unfortunately you do not fit the criteria for this particular survey, however Genactis regularly undertakes surveys relating to a wide range of topics and we trust that you will join us on another occasion.

**[Screen in message]**

Thank you for volunteering to participate in this survey. The study will be launched soon and we will be in contact with you as soon as it is online.

Should you need any assistance throughout this survey please contact:

**[Insert Field manager / MRE name and contact details]**

**E.g. Spain:**

Violeta Pérez

[vperez@genactis.com](mailto:vperez@genactis.com)

Tel. +33 (0)4 92 28 84 37

Introduction

**[UK ONLY –SHOW TO RESPONDENTS IN Q1]**

Recruitment Agreement in line with ABPI Code of Practice Clause 23	
Project Title: <b>Metastatic pancreatic adenocarcinoma</b>	Project No: <b>FG115M01</b>
<b>Nature of Project</b>	
Subject and purpose of market research study: <b>Treatments and usage patterns in metastatic pancreatic adenocarcinoma.</b>	
Methodology and Approach: <b>Quantitative Internet Patient Record collection.</b>	
<b>Fieldwork</b>	
Location: <b>UK</b>	Duration: <b>10 min for the online questionnaire and ~ 30 min per patient record (Target 12 patient records)</b>
Dates: (provisional) June 27 to July 30th	Start Time: <b>online survey</b>
<b>Remuneration</b>	
Type: <b>Bank transfer</b>	Amount: <b>Oncologist: 850 GBP per 10 min questionnaire + 12 patient records of patients treated in 2L</b>
<b>Agreement and Signature</b>	
1. Accept	<a href="#">[CONTINUE]</a>
2. Decline	<a href="#">[TERMINATE]</a>